Replies to post #19028 on Synaptogenix Inc (SNPX)

[urge2surge]

Corporate Communications are bad. No annual shareholders letter or active i.r. here. There's more discovery and information by Runcoach than H.Q.
The upside here is despite the drops, the stock is under accumulation and I have no doubt that Big Pharma has their eyes here. The OBV is extremely bullish despite the current direction. Bryostatin, pipeline product of epic possibilities here. Synaptic regeneration, sustained efficacy, zero toxins, sponsored AD and Fragile X trials.
One of the Big pharma is going to collaborate or take an equity stake here. No way around that. The current market cap and share structures couldn't be more ideal for a partnership. If it doesn't happen, then it'll be due to corporate resistance.

[runncoach]

Just like everyone else I'm guessing covid interrupted some recruiting. Dorcas is as good as mine. Only way we are getting it in 2022 is if they report after the 6 month final dosing and just do the 40 week as I follow up. That would make sense to me but I doubt it goes down that way